The ideal opioid: Is oliceridine the answer?

Abhijit S. Nair, MD

doi:10.5055/jom.2016.0356

Authors

Abhijit S. Nair, MD

DOI:

https://doi.org/10.5055/jom.2016.0356

Keywords:

opioid, side effects, oliceridine

Abstract

There is no ideal opioid available in present clinical practice. Characteristics of an ideal opioid should be rapid onset of action, short acting, minimal respiratory depression, least peripheral side effects like constipation, urinary retention and devoid of dependence or tolerance with chronic use.

Author Biography

Abhijit S. Nair, MD

Consultant Anesthesiologist, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana, India

References

Yang CH, Huang HW, Chen KH, et al.: Antinociceptive potentiation and attenuation of tolerance by intrathecal b-arrestin 2 small interfering RNA in rats.Br J Anaesth. 2011; 107(5):774-781.

Hales TG: Arresting the development of morphine tolerance and dependence. Br J Anaesth. 2011; 107(5): 653-655.

Kraft MD: Emerging pharmacologic options for treating postoperative ileus. Am J Health Syst Pharm. 2007; 64(20 Suppl 13): S13-S20.

Groer CE, Tidgewell K, Moyer RA, et al.: An opioid agonist that does not induce mu-opioid receptor b-arrestin interactions or receptor internalization. Mol Pharmacol. 2007; 71(2): 549-557.

Trevena Inc.: Trevena reports third quarters 2015 financial results and provides corporate update. Nov 10, 2015. Available at: www.trevenainc.com/news-details.php?id=126. Accessed April 8, 2016.